UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2020

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) 45-5320061 (I.R.S. Employer Identification No.)

1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania (Address of principal executive offices)

19355 (Zip Code)

Registrant's telephone number, including area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u> Common Stock, par value \$0.001 per share Trading Symbol TELA Name of Exchange on Which Registered Nasdaq Global Market

Securities registered pursuant to Section 12(g) of the Act:

None

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2020, TELA Bio, Inc. (the "<u>Company</u>") issued a press release announcing its financial results for the quarter ended June 30, 2020. A copy of this press release is furnished as Exhibit 99.1 hereto.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On August 12, 2020, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit	
No.	Document
<u>99.1</u>	Press Release of TELA Bio, Inc., dated August 12, 2020.
<u>99.2</u>	Corporate Slide Deck, dated August 12, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.

By: /s/ Antony Koblish

Name: Antony Koblish

Title: President, Chief Executive Officer and Director

Date: August 12, 2020



TELA Bio Announces Second Quarter 2020 Financial Results

MALVERN, Pa., August 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020.

Recent Highlights

- Reported revenue of \$3.5 million for the second quarter of 2020, increasing 6% over the second quarter of 2019
- Completed an underwritten public offering raising approximately \$45.0 million in net proceeds
- Announced interim analysis from the BRAVO post-market study, showing low hernia recurrence and complication rates
- Proactively managed near-term expenses to control spending and maintain financial flexibility in response to the COVID-19 pandemic

"Our achievements in the second quarter demonstrate our team's resilience and flexibility to continue to support our patients and customers despite the many challenges associated with the pandemic," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "We were pleased by our performance in the quarter, highlighted by the positive interim results we saw with our BRAVO study, the innovative ways in which we have been able to engage our customers virtually, and the completion of a successful follow-on offering. While our results are encouraging, there continues to be uncertainty due to the rapidly evolving environment associated with COVID-19 and the recent outbreaks in certain regions of the country. Despite this, our team remains firmly resolute in achieving our operational objectives and executing our strategic initiatives to ensure that TELA Bio is well positioned for strong growth over the long-term."

Second Quarter 2020 Financial Results

Revenue was \$3.5 million for the second quarter of 2020, an increase of 6% compared to the prior year period. Though our revenue increased over the prior year period, it was impacted by lower than expected procedural volumes as a result of hospitals and patients deferring elective procedures and other factors related to the COVID-19 pandemic.

Gross profit was \$2.1 million for the second quarter of 2020, or 59% of revenue, compared to \$1.9 million, or 58% of revenue, in the same period in 2019. The increase in gross margin was due to the decrease in the charge for excess and obsolete inventory adjustments as a percentage of revenue.

Operating expenses were \$7.3 million in the second quarter of 2020, compared to \$6.2 million in the same period in 2019. The increase was due to the expansion of our commercial organization and increased costs associated with operating as a public company, which was partially offset by the salary reductions, lower travel and consulting expenses resulting from the cost containment actions taken in response to the COVID-19 pandemic.

Loss from operations was \$5.2 million in the second quarter of 2020, compared to a loss from operations of \$4.3 million in the same period in 2019.

Net loss was \$6.1 million in the second quarter of 2020, compared to a net loss of \$5.3 million in the same period in 2019.

Total cash and cash equivalents at June 30, 2020 were \$85.5 million.

Financial Outlook

There is considerable uncertainty and lack of visibility regarding the Company's near-term revenue growth prospects and product development plans due to the rapidly evolving environment resulting from the COVID-19 pandemic. The COVID-19 pandemic is a highly fluid situation and it is not currently possible for the Company to reasonably estimate the impact that it may have on financial and operating results. Accordingly, TELA Bio will not be providing 2020 financial guidance.

Conference Call and Webcast Details

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, August 12, 2020, at 4:30 PM ET.

To participate in the call, please dial (855) 548-1219 (domestic) or (409) 217-8881 (international) and provide conference ID 6897439. The live webcast will be available on the Events & Presentations page of the investors section of TELA's website.

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

Caution Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business of the ongoing COVID-19 pandemic, including but not limited to any impact on our ability to market our products, demand for our products due to deferral of procedures using our products or disruption in our supply chain, our ability to achieve or sustain profitability, our ability to gain market acceptance for our products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing problems, capacity constraints or delays in production of our products, maintenance of coverage and adequate reimbursement for procedures using our product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to updates to our forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under appli

TELA Bio Contact

Stuart Henderson Vice President, Corporate Development and Investor Relations TELA Bio, Inc. 484-320-2930

Investor Contact

Greg Chodaczek 347-620-7010 <u>ir@telabio.com</u>

TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)

	June 30, 2020		Dec	ember 31, 2019
Assets				
Current assets:				
Cash and cash equivalents	\$	85,471	\$	45,302
Short-term investments		—		9,285
Accounts receivable, net		2,586		2,836
Inventory		4,572		4,603
Prepaid expenses and other assets		1,484		2,308
Total current assets		94,113		64,334
Property and equipment, net		678		677
Intangible assets, net		2,759		2,911
Total assets	\$	97,550	\$	67,922
Liabilities and stockholders' equity				
Current liabilities:				
Accounts payable	\$	948	\$	3,171
Accrued expenses and other current liabilities		2,675		3,542
Total current liabilities		3,623		6,713
Long-term debt with related party		30,524		30,243
Other long-term liabilities				4
Total liabilities		34,147		36,960
Stockholders' equity:				
Preferred stock; \$0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding				
Common stock; \$0.001 par value: 200,000,000 shares authorized; 14,413,015 and 11,406,976 shares issued and				
14,412,690 and 11,406,221 shares outstanding at June 30, 2020 and December 31, 2019, respectively		14		11
Additional paid-in capital		244,537		198,829
Accumulated other comprehensive income (loss)		12		(19)
Accumulated deficit		(181,160)		(167,859)
Total stockholders' equity	_	63,403		30,962
Total liabilities and stockholders' equity	\$	97,550	\$	67,922

TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)

	Three mor June			Six mont June	 ded
	2020		2019	 2020	2019
Revenue	\$ 3,507	\$	3,303	\$ 7,233	\$ 6,609
Cost of revenue (excluding amortization of intangible assets)	1,346		1,320	2,796	2,752
Amortization of intangible assets	76		76	152	152
Gross profit	 2,085		1,907	 4,285	 3,705
Operating expenses:					
Sales and marketing	4,123		3,947	9,392	7,942
General and administrative	2,149		1,205	4,667	2,529
Research and development	979		1,055	1,891	2,714
Total operating expenses	 7,251		6,207	 15,950	 13,185
Loss from operations	 (5,166)		(4,300)	 (11,665)	 (9,480)
Other (expense) income:					
Interest expense	(884)		(914)	(1,763)	(1,826)
Change in fair value of preferred stock warrant liability			(74)	—	(38)
Other (expense) income	(31)		27	127	117
Total other (expense) income	 (915)		(961)	 (1,636)	 (1,747)
Net loss	 (6,081)		(5,261)	 (13,301)	 (11,227)
Accretion of redeemable convertible preferred stock to redemption value	_		(2,762)	_	(4,787)
Net loss attributable to common stockholders	\$ (6,081)	\$	(8,023)	\$ (13,301)	\$ (16,014)
Net loss per common share, basic and diluted	\$ (0.53)	\$	(27.06)	\$ (1.16)	\$ (54.06)
Weighted average common shares outstanding, basic and diluted	 11,443,122		296,467	 11,424,952	 296,231
Comprehensive loss:		_		 	
Net loss	\$ (6,081)	\$	(5,261)	\$ (13,301)	\$ (11,227)
Foreign currency translation adjustment	4		1	31	(3)
Comprehensive loss	\$ (6,077)	\$	(5,260)	\$ (13,270)	\$ (11,230)



Forward Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth opportunities, and the effects of company'n actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond the Company's control, including, among others: the impact to the Company's business of the ongoing COVID-19 pandemic, including any impact on the Company's ability to campete successfully, the Company's ability to gain market acceptance for the Company's ability to achieve or sustain profitability, the Company's ability to gain market acceptance for the company's products and to accurately forecast and meet customer demand, the Company's ability to compete successfully, the Company's ability to enhance and experiments for procedures using the Company's products, product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and e



TELA Bio Snapshot

A commercial stage medical technology company marketing a new category of tissue reinforcement materials to address unmet needs in **soft tissue reconstruction**

- Differentiated portfolio of advanced reinforced tissue matrices addressing hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery
- Headquartered: Malvern, Pennsylvania

~\$2B U.S Market Opportunity1

Innovative Products

Improve Clinical Outcomes

Reduce Overall Costs of Care

ninal wall reconstruction and \$0.58 plastic reconstructive surgery.




OviTex: ~\$1.5 Billion Annual U.S. Total Addressable Hernia Market Opportunity

Complex, Moderate Ventral / Abdominal Wall Reconstruction	~\$350 million US market ⁽¹⁾ ~58,000 total procedures per year	
Simple Ventral Hernia Repair	~ \$500 million US market⁽¹⁾ ~326,000 total procedures per year	OviTex ~\$1.5 Billion TAM
Inguinal Hernia Repair	~ \$650 million US market⁽¹⁾ ~711,000 total procedures per year	Opportunity
Hiatal Hernia Repair	~ \$40 million US market ⁽¹⁾ ~40,000 total procedures per year	

Source: Millernium Research Group Reports, IMS Health Data 1) Management estimate. Market size based volume weighted average selling price for OviTex

Hernias Occur Throughout the Abdomen



What is a hernia?

- Occurs when an internal part of the body pushes through a weakness or hole in the muscle or surrounding tissue
 - Natural occurring weakness
 - Weakness from previous surgical incision
- Likelihood of developing a hernia increases with age & obesity

Treating a hernia

- Surgical repair of a hernia with a reinforcing material (mesh) is standard of care
- ~90% of hernia patients receive a mesh repair¹
- Mesh intended to reinforce the defect and provide long-term support



nk LM, Perry KA, Narula VK, Mikami DJ, Melvin WS. Current national practice patterns for inpatient management of ventral abdominal wall hernia in the United States. Surg Endosc. 2013;27(11):4104-4112.

Ventral Hernia: Complex Patient Population

Current Ventral Hernia Treatment Options: No Perfect Product

		Natural Re	pair Products	
BAIRD Ventralight™	Mectronic ProGrip™		<i>OLifeCell</i> Strattice™	Sentrix®
Mectronic Parietex™	Johmon~Johmon PROCEED®	GORE® BIO-A®	INTEGRA	XenMatrix™
Simple Ver	ntral Hernia	Complex, Moderate Ventral Repa	air / Abdominal Wal	Reconstruction

Limitations of Reconstruction Materials Used in Hernia Repair

PERMANENT SYNTHETIC MESH

- Persistent inflammatory response
- Encapsulation of implant
- Chronic post operative pain
- Scar tissue / lack of remodeling
- Mesh infections
- Significant costs of re-operation
- Organ erosion or perforation
- 6,000 related U.S. lawsuits
- Danish Hernia Database: ~17% reintervention at five years¹

RESORBABLE SYNTHETIC MESH

- Inflammatory response until absorbed
- Encapsulation of implant or until absorbed
- Scar tissue / lack of remodeling
- Mesh infection until resorbed
- Organ erosion or perforation
- Lack of mid-term and long-term reinforcement
- Recurrence rate of 12% at 18months follow-up²


BIOLOGIC MATRICES

- Lack of strength or durability
- Prone to laxity and stretching
- Difficulty in surgeon handling
- Difficult using in robotic surgery / LAP
- High costs
- RICH study: recurrence rates of 22% and 33% at 12-months and 24-months follow-up, respectively³



Kokotovic, Bisgaard and Helgstrand, Long-term Recurrence and Complications Associated With Elective Incisional Hernia Repair. JAMA. 2016;316(15):1575-1582. doi:10.1001/jama.2016.15217 (on-line)
 Roth, JS et. al. (2017) "Prospective evaluation of pdy-4-hydrogbulyrate mesh in CDC class Uhigh-risk ventral and incisional hernia repair: 18-month follow-up." Surgical Endoscopy.
 Roth, JS et. al. (2012) "Prospective study of single-stage repair of contaminated hernias using a biologic porcine tissue matrix: The RICH Study" Surgery

Our Solution: New Category of Tissue Reinforcement Materials



High Quality Biologic Material Drives Technology Platform

TELA maintains a definitive license agreement with Aroa BioSurgery for the use of ovine rumen

- ^a Aroa has two issued patents protecting the use of ovine rumen for use as a source of extracellular matrix
- Exclusive license in North America and Europe for hernia repair, abdominal wall and breast reconstruction
- ^a Ovine rumen is high quality biologic source material, sourced from New Zealand and subject to strict quality controls
 - Plentiful supply ~27 million sheep in New Zealand
 - Low cost of goods
 - Homogenous, intact, minimally processed material lends itself to be a good building block for fabrication into medical devices
- Aroa recently completed its IPO and is listed on the ASX (ticker: ARX.AX)

TELA	Aroa BioSurgery
 Product development, commercial strategy & execution and clinical data generation Revenue sharing agreement based on net sales; TELA retains 73% of net sales 	 Manufacturing and supply of product Aroa receives 27% of net sales
	10


AROA

Our Solution: A New Category of Soft Tissue Reinforcement Materials

	Designed in close collaboration with more than 100 surgeons	
Improve Performance Over Existing Reconstruction	 Products designed with over 95% biologic material (<5% polymer/synthetic content) 	
Materials	Benefits of both biologic materials and polymer materials	
	 Supports range of surgical techniques 	
	Reduced foreign body inflammatory response	
Improved Biologic Response		
	Enhanced remodeling of soft tissue and rate of healing	
Lower Upfront Costs	 Customers realize ~20% to 40% cost-savings over leading biologic materials and resorbable synthetic mesh 	
	Provides benefits of advanced biologic repair to more patients	
TELA BC		11

OviTex: a New Approach to Soft Tissue Reconstruction for Hernia Repair and Abdominal Wall Reconstruction

An innovative reinforced tissue matrix designed to reduce stretch compared to biologic matrices and longterm complications experienced with resorbable and permanent synthetic meshes



Comprehensive Portfolio for a Range of Hernia Types & Surgical Techniques

Each configuration is available with either permanent (polypropylene) polymer or resorbable (polyglycolic acid) polymer reinforcing the same biologic material.

OviTex 4-layer device, not intended for intraperitoneal placement Strength*: + Common Procedures: Moderate ventral

hernia (pre-peritoneal placement), inguinal hernia, hiatal hernia OviTex 1S

6-layer device, with "smooth side" suitable for intraperitoneal placement Strength": ++ Common Procedures: Moderate to complex ventral hernia



OviTex 2S 8-layer device, with 2 "smooth sides" suitable for intraperitoneal placement Strength": +++ Common Procedures: Complex ventral herria and abdominal wall reconstruction and can be used for bridging



Images represent permanent polymer Ov/Tex products. Resorbable polymer products have clear polymer. ¹ Biomechanical data on file.

OviTex LPR for Laparoscopic & Robotic-Assisted Repair

- OviTex LPR is specifically tailored for robotic-assisted hernia surgical repairs
 - ^o Significant increase in robotic hernia repairs in last few years
 - Robotic-assisted hernia repair provides the benefits of laparoscopic repair
 - Designed for improved surgical handling, access, and primary closure of hernia
 - Designed for use with a trocar
- 4 total SKUs available, following commercial introduction of 3 additional SKUs in December 2019
- Products expected to be used most frequently in simplemoderate ventral hernia patients







Disruptive Technology Supported by a Compelling Body of Clinical Evidence



92 Adult Patient, Prospective, Single Arm, Multicenter BRAVO Study

- 0 (0%) hernia recurrence in first 20 patients at 24-months
- 1 (2%) hernia recurrence in first 57 patients at 12-months

14 clinical publications

- Strong clinical efficacy and low complication rates in range of hernias
- Recent poster presentations at MISS conference highlighting use of OviTex products in robotic repair

More than 200 Non-Human Primates

OviTex demonstrates more rapid tissue integration and revascularization compared to biologic matrices and lower inflammatory response and better functional tissue remodeling compared to permanent and resorbable synthetic mesh

Continue to build clinical evidence

^o Plan to initiate a post-market study of OviTex in robotic-assisted hernia repair surgery



A fixed fixey that, for fixed the Reserves in the Anticipation of the State	n Reinforceannan Mhoris ma Loward Marria Na Righead Alan Palaonia
BOUGHT IN	A Logical control of the physical distance of
BERRE Van	
in your man	
TRIB	
And States of Lands	Constant and

Multiple Future Analyses of BRAVO Data Planned for 2020

Q1 2020	Q2 2020	Q3 2020	Q4 2020
20-patients at 24-months			 ~75 patients at 12-months
57-patients at 12-months			 ~50-patients at 24-months
 84-patients at 3-months 			
 Additional information on surgical 	site occurrence rate will also b	be analyzed	
Study design allows for robotic surgical technique	, laparoscopic and open im	plantation of OviTex 1S, allo	wing for sub-analyses by
Data will be automitted to reading	al journals and for present	ation at key medical conferen	aces throughout the year

OviTex BRAVO Study Shows Low Recurrence Rate at 12 and 24-months

Product Name	<u>Study</u> Tissue Reinforcement Material		Hernia Recu	rrence Rate		mber of Hernia Recurrence	Number of Patients who Completed Follow-up	Follow-up Period in Months
OviTex	Reinforced Tissue Matrix	2%				1	57	12
OviTex	Reinforced Tissue Matrix	0%				0	20	24
Results from F	Post-Market Clinical Studies of Tissue Reinforcement Material		laterials Hernia Recur	rence Rate ¹		nber of Hernia Recurrence ¹	Number of Patients who Completed Follow-up ¹	Follow-up Period in Months
Phasix	Resorbable Synthetic Mesh	5%				5	95	12
Phasix	Resorbable Synthetic Mesh		12%			11	95	18
Phasix	Resorbable Synthetic Mesh			23%		19	82	36
Strattice	Biologic Matrix			22%		15	69	12
Strattice	Biologic Matrix				33%	22	67	24

1) Hernia Recurrence Rate based on number of hernia recurrences reported in patients who completed follow up and patients who reported recurrent hernia before the specified follow up period. Clinical Revature and conference presentations included hernia recurrence in patients who completed follow up period end and report hernia recurrence.

We believe Plastic and Reconstructive Surgery Represents a Significant Market Opportunity

- Use of biologic matrices validated by growing clinical literature
- Biologics provide the following clinical benefits:
 - Ability to define shape and position
 - Soft tissue reinforcement
 - Improvement of tissue quality
 - Aids in defining the pocket and allows for more immediate tissue expansion
 - Reduced inflammatory response
- Existing biologics are costly, prone to excessive stretch over time, and difficult for surgeons to handle



te: Management estimate. Market size based on sales of current biologics


~\$500 Million Annual U.S. Market Opportunity

Uses

- Breast reconstruction
- Head and neck surgery
- Chest wall reconstruction
- Pelvic reconstruction
- Extremities reconstruction

OviTex PRS: Purposely Designed for Plastic and Reconstructive Surgery

An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch



TELA BO


Commercial Organization

- 41 sales territories at June 30, 2020
 - OR-based Account Managers call on General, Plastic Recon, Colorectal & Trauma surgeons
 - Carry full OviTex & OviTex PRS portfolio
- 6 sales regions
 - Plan to scale existing regions until each region has ~8 territories
- Territories supported by Clinical Development and Strategic Customer Relations teams





R	=ocus	sed on Driving Utilization within Accessed Accounts	
	*	Contracts in place with multiple national and regional Group Purchasing Organizations (GPOs)	
	â	Current GPO contracts provide access to ~1,900 hospitals across the U.S., estimated to perform over ~135,000 addressable soft tissue reconstruction procedures per year ¹	
	٢	Data-driven, targeted implementation strategy	
	њ	Account Manager hiring for new territories focused on areas with high concentrations of accessed accounts	
	TEL	1. Data based on estimates from Definitive Healthcare and IOVIA Hospital Procedure and Diegnosis data.	21



Revenue Growth



Q1 2020 quarterly revenue impacted by COVID-19 pandemic beginning mid-March 2020 and continued throughout Q2 2020



Statement of Operations

	Three months Ended June 30	
	2020	2019
Revenue	\$3.5	\$3.3
Cost of revenue	1.3	1.3
Amortization of Intangible Assets	0.1	0.1
Gross profit	\$2.1	\$1.9
Gross margin	59%	58%
Operating expenses:		
Selling and Marketing	4.1	3.9
General and Administrative	2.2	1.2
Research and Development	1.0	1.1
Total operating expenses	7.3	6.2
Loss from operations	(\$5.2)	(\$4.3)
Other (expense) income, net	(0.9)	(1.0)
Net loss	(\$6.1)	(\$5.3)

 Revenue increased 6% over prior year period

 Total cash and cash equivalents at June 30, 2020 were \$85.5 million

Q2 2020 revenue impacted by COVID-19 pandemic



